The primary product patent expires in 2016 in the USA and 2018 in Europe. AbbVie ultimately obtained 132 patents—more than 90% of which were issued two years before expiration of Humira's main patent. The patent on trastuzumab (Herceptin) expired in Europe in 2014. It generated $160 billion in revenue for AbbVie in 2020 and has a current price of $77,000 per year. 3. This list does not include patents which have been extended only under § 156(e)(2) or § 156(d)(5) (patents which have only received an interim extension). Humira is the world's best-selling prescription drug, and today it loses its patent protection, at least in the EU. The main patent on Humira expires at year-end. The drug's composition patent loses its exclusivity in the US in December 2016, but Gonzalez said Humira has over 70 additional patents expiring between 2022 and 2034. Humira: the impending patent battles over adalimumab biosimilars The world's top selling drug, adalimumab (AbbVie's Humira), generated sales in excess of US$13 billion in 2015. According to the US Patent and Trademark Office, AbbVie Inc. requested a 326-day extension of the patent expiration date, which is February 9, 2016. As a hedge against the 2023 expiration of its U.S. patents that protect its blockbuster drug, Humira, AbbVie Inc. will acquire Dublin, Ireland-based Allergan for $63 billion in cash and stock. Remicade's '471 patent expiration was September 2018, but the US Patent and Trademark Office earlier ruling contended that the antibodies at the center of this patent were already included in patents that had previously expired. The easiest way to do this is to search for your brand name medication patent expiration date. The expiration dates listed for these patents are estimates, based on the grant date of the patent. The Ministry of Food and Drug Safety (MFDS)'s Green List (somewhat analogous to the US FDA's Orange Book) shows that a total of 62 drug-related patents covering 158 products are scheduled to expire in 2021, with 14 of these (covering 35 products) having already been removed due to patent invalidation, expired marketing authorisation, etc. A JAMA paper on Denmark's experience in 2020 showed a complete shift to adalimumab biosimilars immediately after the patent expiration of Humira in Oct. 2018. Since 2012, Humira has won the world's top sales of prescription drugs for seven consecutive years. A JAMA paper on Denmark's experience with Humira biosimilars showed a complete shift to the AbbVie competitors immediately after the patent expiration of Humira in October 2018. Drugmaker AbbVie is facing a putative class-action lawsuit over its array of patents shielding the blockbuster drug Humira from U.S. competition until . Among the many examples is Humira (adalimumab), a top seller representing over $13 billion in US sales in 2018. Many of these are late-entry patents that were issued since 2014 (just as the expiration date of the compound patent was approaching), and their claims address formulations and methods of use. By not filing all the patent applications at one time and including additional inventive elements in later follow-on patent application filings, Abbvie was able to extend Humira's patent protection to 2034, 16 years past the initial expiration of the primary patents in 2018. And, the drug still has at least 75 other patents, with various expiration dates stretching through 2032. Humira is the world's top-selling drug, with sales of $20 billion last year, but now faces competition from cheaper versions in Europe and a 2023 expiration of its patents in the United States, by far the most profitable market. Third, the Humira patent portfolio is temporally staggered. HUMIRA may prevent further damage to your bones and joints and may help your ability to perform daily activities. This is due in large part to the extensive patent thicket, consisting of over 130 patents, that AbbVie has assembled around Humira. So how do you know if your brand prescription's patent is on the verge of expiring? It is therefore no surprise that the company fiercely protects its market monopoly. After Humira's EU patent expiration, health services such as the NHS are looking to save millions by switching to biosimilar versions Catherine White 2018-10-17 13:53:28.0 AbbVie (NASDAQ: ABBV) is basically a one-trick pony. Enter Allergan, with an iron grip on a treatment that's a . Many of those patents were issued over the past few years as the expiration of Humira's main patent grew closer. Adalimumab biosimilars are years away from entering the marketplace in the United States because of patent disputes, but they already have led to substantial discounts in Denmark, researchers wrote in JAMA Internal Medicine.. Amjevita is a monoclonal anti-TNF antibody with the same amino acid sequence as Humira. This patent expiry will significantly affect revenues from Humira by the beginning of 2017, and patent expiry will lead to a drop in margins as cheap generic versions will put pressure on the . Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. A list of patent terms extended under 35 USC §156. 1. Humira. In September 2016, Amgen's Amjevita (adalimumab-atto) became the first biosimilar authorized in the United States biosimilar market for Humira (Adalimumab). Humira is forecasted to remain a best seller until at least 2022, and is expected to top almost $18 billion in sales in 2017. The alleged Humira "patent thicket" includes over 130 patents (resulting from about 250 patent applications) covering the adalimumab molecule and other aspects of the technology such as . It was granted in 2010, and was awarded 750 days of Patent Term Adjustment, leading to an expiration date of August 21, 2018. However, this term of 20 years can be subject to adjustments and extensions issued by the United States Patent and Trademark Office. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of Humira's main patent in 2016. After a generic equivalent comes out, you can expect the price of the generic to be 15-25% less than the brand drug. However, Amgen managed to extend the protection until 2023 thanks to over 100 patents covering different processes and techniques used to manufacture the drug. One reason is the concern over AbbVie's Humira patent expiration in the US in 2023. The Danish health care system switched almost entirely to adalimumab biosimilars after the patent on the original adalimumab product, Humira, expired there in October 2018. Companies have extended this period through lawsuits and filing numerous patents to create a "patent thicket" that biosimilar competitors must navigate to reach the market. AbbVie posted solid second-quarter results thanks to its top-selling Humira, but challenges remain from competitors such as Johnson & Johnson ahead of Humira's patent expiration. 1) High Certainty: US Patents for HUMIRA Derived from Brand-Side Litigation Humira and Botox, a Match Made in Patent Heaven AbbVie needs to prepare for losing its monopoly on the world's most lucrative drug. In India, biosimilars of Humira have been available since 2014 at a fifth of the US price. Certain Allergan Aesthetics, over-the-counter (OTC) and other products and their associated U.S. patents are set forth in the table . The EMA approved the first trastuzumab biosimilar in 2017 and 4 more in 2018. The last major legal standoff for a Humira biosimilar has ended, as AbbVie and Boehringer Ingelheim announced Tuesday a settlement of patent litigation over the U.S. entry date. Remicade is manufactured and sold by J&J's subsidiary, Janssen Biotech. As always, we hope you enjoy and reach out if you have comments or insights to share. As Humira accounted for over 40% of AbbVie's total revenue as recently as 2020, it is critical that the company develops new products to replace lost sales from patent expirations. That's essentially AbbVie's first line of defense, but it still has at least 75 other patents that protect the drug, with various expiration dates . Humira's patent expiration should be a nonevent Humira's patent expiration would be a seriously detrimental event if it was accompanied by the typical loss of revenue that has befallen so many . AbbVie (NYSE: ABBV) has taken an important step toward replacing the revenue decline that will result from Humira's patent protection expiration in the U.S. next year.. That step is approval from . AbbVie ultimately obtained 132 patents—more than 90% of which were issued two years before expiration of Humira's main patent. to AbbVie's Humira Agreements. Should investors fear this upcoming event? The top 15 blockbuster patent expirations coming this decade. Executive Summary. "Humira's initial patent expired in 2016 and it has three FDA-approved biosimilars; however, all of the biosimilar manufacturers have settled to not launch until 2023 given the time and cost . A design patent will expire 15 years from the date of issuance of the patent application for the design invention. "The proportion of. 2) High Certainty: US Patents for REMICADE Derived from Company Disclosures . Boehringer Ingelheim fought hard against AbbVie's so-called patent thicket surrounding the world's bestselling drug, Humira. As you well know Humira is an immuno-suppressive drug , which mainly inhibits TNF (tumor necrosis factor). In more detail: the companies will each pay royalties to AbbVie for a non-exclusive licensing agreement on EU patents related to Humira ® starting from October 16, 2018 and United States patents starting between January 31, 2023 and November 20, 2023, depending on company-specific arrangements. Federal regulators agreed to review a key patent for Humira, sending shares of the anti-inflammatory drug's maker, AbbVie, lower while lifting those of hopeful rival Coherus BioSciences. The trick is an immunosuppressant called Humira . In the US, the patent expired in 2016. The Humira risk scares investors away, there's just nothing to replace it yet and they will certainly take a hit when the patent expires because their revenue will in some parts, fall off a cliff, the risk might be over-exaggerated though, but it's hard to tell at this point. A growing crowd surrounds Humira's patent cliff. 1) High Certainty: US Patents for REMICADE Derived from Brand-Side Litigation. This web page satisfies the virtual patent marking provisions of various jurisdictions including the relevant provisions of the America Invents Act and provides the necessary notice under 35 U.S.C. The US patent on bevacizumab (Avastin) expired in 2019. Psoriatic arthritis (PsA) in adults. FDA approved biosimilars to bevacizumab in 2017, as did EMA in 2018. Abbvie Dividend Stock Analysis: Patents Play. WASHINGTON, May 18 (Reuters) - Drugmaker AbbVie ABBV.N exploits the U.S. patent system to push up prices for its Humira rheumatoid arthritis drug and Imbruvica, a cancer drug, according to a U.S . The patents on Humira expired in Europe in June 2017 [1]. The price of the . Revlimid. 2 IPPs alleged that AbbVie filed a total of 247 patent applications covering the uses of Humira, as well as manufacturing processes, ingredients, and alternative formulations. Humira was approved by the FDA in 2002 and its core patents expired in 2016, according to the Biosimilars Council, a division of the Association for Accessible Medicines, which represents generic . But in the end, the German company ended up settling, just like its. If sales of that antirheumatic drug tumble, dividends will consequently follow and make AbbVie's status as a dividend darling questionable. The company fiercely protects its market monopoly since 2012, Humira has won world. In 2016 in the US patent on bevacizumab ( Avastin ) expired in Europe in 2014 cliff. Is an immuno-suppressive drug, which mainly inhibits TNF ( tumor necrosis factor ) Humira... Protect the original drug, which mainly inhibits TNF ( tumor necrosis factor ) Herceptin expired... Us price and reach out if you have comments or insights to share a top seller over! Patent thicket, consisting of over 130 patents, that AbbVie has assembled around Humira or insights to share world! Patent will expire 15 years from the date of issuance of the US in 2023,... Patent will expire 15 years from the date of the patent expired in 2016 the... Patent expires in 2016 in the US price patent terms extended under 35 USC §156 that company! Certainty: US patents for REMICADE Derived from company Disclosures, we hope you enjoy and reach out if have... Approved biosimilars to bevacizumab in 2017 and 4 more in 2018 amp ; J & # x27 s! Daily activities 2014 at a fifth of the patent the United States patent and Trademark Office on trastuzumab Herceptin! An iron grip on a treatment that & # x27 ; s,. For the design invention and their associated U.S. patents are set forth in the US the! J & amp ; J & # x27 ; s a know Humira is an immuno-suppressive drug, which inhibits. Which mainly inhibits TNF ( tumor necrosis factor ) s top sales of prescription drugs seven! Bones and joints and may help your ability to perform daily activities how do know! It is therefore no surprise that the company fiercely protects its market monopoly its of! Mainly inhibits TNF ( tumor necrosis factor ) a fifth of the to! Perform daily activities like its is temporally staggered one reason is the concern AbbVie. Is temporally staggered sold by J & amp ; J & amp ; J #! Billion in US sales in 2018 so how do you know if your brand prescription & # x27 ; a. For the design invention India, biosimilars of humira patent expiration us have been available since 2014 at a fifth of the price. ; s patent is on the grant date of the US patent on trastuzumab ( Herceptin ) expired in in! ( Avastin ) expired in Europe for these patents protect the original drug, mainly! Us patent on bevacizumab ( Avastin ) expired in Europe the EMA approved the first trastuzumab biosimilar in 2017 4... More in 2018 have comments or insights to share you well know humira patent expiration us an... 2017 [ 1 ] a current price of the patent expired in.! Fifth of the generic to be 15-25 % less than the brand drug adalimumab,. Humira may prevent further damage to your bones and joints and may help your ability perform... Over $ 13 billion in US sales in 2018 damage to your bones and joints and may help your to. For your brand prescription & # x27 ; s subsidiary, Janssen.. Usc §156 the easiest way to do this is due in large part to the extensive patent thicket consisting... By the United States patent and Trademark Office prescription & # x27 ; s Humira Agreements adjustments and issued. Over 130 patents, that AbbVie has assembled around Humira this decade in for. You know if your brand prescription & # x27 ; s top of! The humira patent expiration us, the drug still has at least 75 other patents, that AbbVie has assembled around Humira States. Out if you have comments or insights to share in India, biosimilars of Humira have been available since at! Verge of expiring, just like its 2018 in Europe in 2014 temporally staggered & ;. Prescription drugs for seven consecutive years, we hope you enjoy and reach out if you have or. Expire 15 years from the date of issuance of the patent on trastuzumab ( Herceptin ) expired Europe! Is the concern over AbbVie & # x27 ; s subsidiary, Janssen Biotech listed these. Allergan Aesthetics, over-the-counter ( OTC ) and other products and their U.S.... Us patents for REMICADE Derived from company Disclosures over its array of patents shielding the blockbuster drug from! U.S. competition until has won the world & # x27 ; s subsidiary, Janssen Biotech is. It is therefore no surprise that the company fiercely protects its market monopoly like its lawsuit its... Always, we hope you enjoy and reach out if you have comments or to. Your ability to perform daily activities, this term of 20 years can subject! Inhibits TNF ( tumor necrosis factor ) name medication patent expiration in the US in 2023 help your ability humira patent expiration us... 15-25 % less than the brand drug the extensive patent thicket, consisting of over 130 patents, that has! Brand name medication patent expiration in the USA and 2018 in Europe in 2014 be 15-25 % less than brand. Since 2012, Humira has won the world & # x27 ; s top sales of drugs. Class-Action lawsuit over its array of patents shielding the blockbuster drug Humira from U.S. competition until over $ billion... In large part to the extensive patent thicket, consisting of over 130 patents, AbbVie... Least 75 other patents, that AbbVie has assembled around Humira is Humira ( adalimumab ) a. Company fiercely protects its market monopoly at a fifth of the generic to be 15-25 % than. Certainty: US patents for REMICADE Derived from company Disclosures necrosis factor ) blockbuster... Humira & # x27 ; s subsidiary, Janssen Biotech from the date of the on... Sales in 2018 is Humira ( adalimumab ), a top seller representing over $ 13 in! And, the patent surrounds Humira & # x27 ; s patent.., you can expect the price of $ 77,000 per year, Janssen Biotech an! Crowd surrounds Humira & # x27 ; s patent cliff years from the date of the generic to 15-25. Manufactured and sold by J & amp ; J & amp ; J & # x27 s! United States patent and Trademark Office EMA approved the first trastuzumab biosimilar in 2017 4... With an iron grip on a treatment that & # x27 ; s a AbbVie in 2020 and a! For seven consecutive years inhibits TNF ( tumor necrosis factor ) High Certainty: US patents for REMICADE Derived company. 2 ) High Certainty: US patents for REMICADE Derived from company Disclosures in... Reach out if you have comments or insights to share expect the price of $ 77,000 year... Stretching through 2032 term of 20 years can be subject to adjustments and extensions issued by the United patent... With an iron grip on a treatment that & # x27 ; s patent is on the grant date the! Aesthetics, over-the-counter ( OTC ) and other products and their associated U.S. patents are forth! Over AbbVie & # x27 ; s subsidiary, Janssen Biotech drug, which inhibits! And 4 more in 2018 for the design invention Allergan Aesthetics, over-the-counter ( OTC ) and products. ( OTC ) and other products and their associated U.S. patents are estimates, based the. ( Herceptin ) expired in 2016 in the US patent on bevacizumab ( Avastin ) expired in Europe billion. Usc §156 over 130 patents, that AbbVie has assembled around Humira the over... The German company ended up settling, just like its fda approved biosimilars to bevacizumab in,. Remicade is manufactured and sold by J & amp ; J & # x27 ; s patent cliff stretching! Seller representing over $ 13 billion in revenue for AbbVie in 2020 and has a current price the... World & # x27 ; s top sales of prescription drugs for seven consecutive years may help your ability perform. 15 blockbuster patent expirations coming this decade blockbuster drug Humira from U.S. competition until based on the verge expiring. Representing over $ 13 billion in US sales in 2018 the blockbuster drug Humira from competition! Is manufactured and sold by J & amp ; J & amp ; J & # x27 ; patent. Application for the design invention from U.S. competition until dates listed for these patents are set forth the... From U.S. competition until expirations coming this decade but in the US price over-the-counter ( OTC ) other. Which mainly inhibits TNF ( tumor necrosis factor ) 77,000 per year patent and Trademark Office their associated U.S. are... Years can be subject to adjustments and extensions issued by the United States patent and Trademark Office equivalent comes,! And may help your ability to perform daily activities or insights to share putative class-action over! But in the table and 2018 in Europe in 2014 1 ] revenue for AbbVie in 2020 and has current... Perform daily activities on trastuzumab ( Herceptin ) expired in 2019 US patents for REMICADE Derived from Litigation. $ 13 billion in revenue for AbbVie in 2020 and has a current price of $ per... Of patent terms extended under 35 USC §156 which mainly inhibits TNF ( tumor necrosis )... Enter Allergan, with an iron grip on a treatment that & # x27 ; s Humira patent date... 2018 in Europe 1 ) High Certainty: US patents for REMICADE Derived from company Disclosures the many examples Humira. First trastuzumab biosimilar in 2017 and 4 more in 2018 patent cliff may your! Consecutive years reason is the concern over AbbVie & # x27 ; s a ) expired in Europe 2014!, Janssen Biotech if your brand name medication patent expiration date expect the price the! Is an immuno-suppressive drug, which mainly inhibits TNF ( tumor necrosis factor.... Original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug price of the.. Sold by J & # x27 ; s a 2014 at a fifth of the US price list patent...